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Abstract: This study investigated genomic differences in Australian and Indian Pseudomonas aeruginosa
isolates from keratitis (infection of the cornea). Overall, the Indian isolates were resistant to
more antibiotics, with some of those isolates being multi-drug resistant. Acquired genes were
related to resistance to fluoroquinolones, aminoglycosides, beta-lactams, macrolides, sulphonamides,
and tetracycline and were more frequent in Indian (96%) than in Australian (35%) isolates (p = 0.02).
Indian isolates had large numbers of gene variations (median 50,006, IQR = 26,967–50,600) compared
to Australian isolates (median 26,317, IQR = 25,681–33,780). There were a larger number of mutations
in the mutL and uvrD genes associated with the mismatch repair (MMR) system in Indian isolates,
which may result in strains losing their efficacy for DNA repair. The number of gene variations were
greater in isolates carrying MMR system genes or exoU. In the phylogenetic division, the number of core
genes were similar in both groups, but Indian isolates had larger numbers of pan genes (median 6518,
IQR = 6040–6935). Clones related to three different sequence types—ST308, ST316, and ST491—were
found among Indian isolates. Only one clone, ST233, containing two strains was present in Australian
isolates. The most striking differences between Australian and Indian isolates were carriage of exoU
(that encodes a cytolytic phospholipase) in Indian isolates and exoS (that encodes for GTPase activator
activity) in Australian isolates, large number of acquired resistance genes, greater changes to MMR
genes, and a larger pan genome as well as increased overall genetic variation in the Indian isolates.
Keywords: antibiotic susceptibility; WGS; phylogenetic analysis; DNA mismatch repair system
1. Introduction
Pseudomonas aeruginosa is a ubiquitous bacterium which can cause opportunistic or nosocomial
infections in immuno-compromised patients [1]. P. aeruginosa commonly causes corneal (keratitis) [2],
respiratory, burn and wound infections, and infections related to medical or surgical devices including
ventilator-associated pneumonia [3,4]. P. aeruginosa corneal infections are usually related to contact
lens wear, but other risk factors for keratitis in non-contact lens wearers include ocular trauma,
ocular surgery, and prior ocular surface disease [5–8].
The prevalence of multi-drug resistant (MDR) or extensively drug resistant strains of P. aeruginosa
reduces treatment options, significantly increasing morbidity rates [9]. P. aeruginosa is naturally
resistant to some antibiotics due to the possession of specific resistance genes such as catB that confers
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chloramphenicol resistance and an inducible ampC which encodes for a β-lactamase that hydrolyses
cephalothin and ampicillin, conferring resistance toβ-lactams [10]. Additionally, the regulation of efflux
pumps also contributes towards an elevated resistance to antibiotics [11]. For example, expression
of the efflux pump MexAB-OprM contributes towards intrinsic resistance to a broad spectrum
of antibiotics [12], whereas the efflux pump MexXY-OprM is involved in the adaptive resistance
to aminoglycosides [13]. Other resistance mechanisms in P. aeruginosa include the acquisition of
transferrable resistance determinants, including those associated with transposons and integrons [14].
Antibiotic resistance of P. aeruginosa varies according to the region where the strains have been
isolated [15,16] presumably due to the prescribing practices, availability of antibiotics, and perhaps
their use in animal husbandry. Various epidemiological studies have identified MDR P. aeruginosa from
different infections and these isolates have acquired different resistance characteristics. For example,
aminoglycoside resistance [17] and ciprofloxacin persistence [18] are found in cystic fibrosis isolates of
P. aeruginosa. Some of these MDR strains are clonal and such clonal strains are often the predominant
global clinical MDR isolates [19] which spread resistance characteristics into the wider population
which enables clonal lineages to expand with time.
ExoU has been associated with virulence of P. aeruginosa at the ocular surface. ExoU is a
phospholipase that causes mammalian cell death [20] and exoU possession is common in strains
isolated from ocular infections [21]. There is a correlation between carriage of exoU and elevated
resistance to fluoroquinolones and aminoglycosides [22]. ExoU is carried by strains on a genomic
island that also contains resistance genes for a range of antibiotics [23].
In addition to the acquisition of resistance genes, bacteria can develop resistance through mutation
of genes so that antibiotic targets are modified. Mutation rates are elevated in strains that carry
mutations in DNA mismatch repair (MMR) systems and hence such mutator strains will normally carry
more mutations than non-mutator strains [24]. In P. aeruginosa, the MMR system is composed of mutS,
mutL, and UvrD genes [25]. Strains of P. aeruginosa isolated from the lungs of cystic fibrosis patients
have alterations in the DNA MMR system and this has been correlated with multiple antimicrobial
resistance [23].
In Australia, there is a tight regulation of prescribing antibiotics, and antibiotics can only be
obtained legally with a prescription from a qualified healthcare professional according to the Therapeutic
Goods Act 1989. In India, on the other hand, whilst branded antibiotics exist, other forms such as
counterfeit, substandard, and ‘spurious’ antibiotics have been reported [26], making surveillance and
regulation difficult [27]. While the antibiotic consumption per person in Australia and India in 2010
was approximately similar, there was a more rapid increase between 2000 and 2010 in India [28].
These differences may affect antibiotic resistance development.
The aim of the current study was to compare the phenotypic resistance and genetic characteristics
associated with resistance between strains isolated from Australia and India to better understand the




The minimum inhibitory concentrations (MICs) and minimum bactericidal concentrations (MBCs)
of the P. aeruginosa isolates were determined (Table 1). Strains showing intermediate resistance (I)
as well as full resistance to antibiotics were categorized as resistant (R) for subsequent analyses.
Based on the Centers for Disease Control and Prevention’s (CDC, Atlanta, GA, USA) definition of
multi-drug resistance as “an isolate that is resistant to at least one antibiotic in three or more drug
classes”, isolates 198, 202, 216, 217, 218, 219, 220, and 221 were deemed to be multi-drug resistant.
Australian isolates 223, 224, 225, 227, 233, and 235 were also resistant to three antibiotics but these
antibiotics were not of different classes. Isolates 176, 193, and 206 were sensitive to all antibiotics, but all
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other isolates were resistant to at least one antibiotic. Overall, Indian isolates were more resistant to
antibiotics compared to Australian isolates. Among Australian isolates (n = 14), resistance was 78%
for imipenem, 57% for ceftazidime, 50% for ciprofloxacin, 21% for piperacillin, 14% for levofloxacin,
7% for tobramycin, and no isolates were resistant to gentamicin or polymyxin. In contrast, resistance in
Indian isolates (n = 12) was 75% for ciprofloxacin, 58% for imipenem, 50% for levofloxacin, tobramycin,
and ceftazidime, 41% for piperacillin, 40% for gentamicin, and 25% for polymyxin.
Table 1. Minimum inhibitory concentration (MIC) and minimum bactericidal concentration (MBC) of
antibiotics to Pseudomonas aeruginosa keratitis isolates.
Strain











































123 1/1 1/1 0.25/0.5 4/4 8/16 4(I)/8 2/2 1280(R)/1280
126 0.5/1 0.5/1 0.5/1 0.25/0.5 8/16 8(R)/16 128(R)/256 1/1
127 1/2 0.25/1 2/4 32(R)/128 4/16 4(I)/8 128(R)/256 0.5/1
162 0.5/1 0.5/1 0.25/0.5 0.25/1 8/8 4(I)/4 2/4 0.25/0.5
169 2(I)/4 0.25/0.5 0.25/0.5 0.25/0.5 4/8 2/4 1/2 0.25/0.25
176 0.5/1 0.25/0.5 0.25/0.5 0.25/0.5 4/8 2/8 2/4 0.25/0.5
181 1/4 0.25/0.5 0.25/0.5 0.25/0.5 32(R)/64 4(I)/8 16(I)/32 0.5/1
182 1/2 0.25/0.5 0.25/0.5 0.25/0.5 4/8 8(R)/16 1/2 0.25/0.5
223 64(R)/128 1/2 0.5/1 0.5/1 160(R)/320 1/2 16(I)/32 2/4
224 16(R)/32 1/2 0.25/0.5 0.25/0.5 8/16 64(R)/128 16(I)/32 1/2
225 64(R)/128 16(R)/32 0.5/2 1/2 16/32 64(R)/128 8/16 0.25/0.5
227 64(R)/128 64(R)/128 0.5/1 0.25/1 16/32 16(R)/32 16(I)/32 0.25/0.5
233 8(R)/16 1/2 1/2 105/1 16/32 4(I)/8 160(I)/320 0.5/1
235 16(R)/32 0.5/1 2/4 0.5/1 64(R)/128 4(I)/8 64(I)/128 0.25
188 2(I)/4 1/2 0.5/1 32(R)/64 16/65 0.5/1 4/8 2/4
189 0.25/1 1/2 0.25/0.5 16(R)/32 4/8 2/1 8/16 2/4
193 1/1 0.25/1 0.25/0.25 0.25/0.5 4/8 2/4 2/2 0.5/1
198 1280(R)/2560 320(R)/1280 2560(R)/5120 16(R)/16 8/8 1/2 8/8 4(I)/4
202 640(R)/1280 320(R)/640 8(I)/32 320(R)/640 16/64 8(R)/32 8/32 0.25/0.25
206 1/1 0.5/0.5 1/1 0.25/0.5 8/8 2/4 2/4 0.25/0.5
216 64(R)/128 4 (I)/8 1/2 0.5/2 160(R)/320 16(R)/32 64(R)/128 64(R)/128
217 64(R)/128 32(R)/64 1/2 1/2 64(R)/128 8(R)/16 32(R)/64 0.25/1
218 8(R)/16 1/2 0.5/1 0.5/1 160(R)/320 8(R)/16 64(R)/128 1/4
219 ≥5120(R)/≥5120 640(R)/1280 ≥5120(R)/≥5120 1280(R)/2560 2560(R)/5120 40(R)/80 16(I)/32 0.25/1
220 2(I)/4 0.25/0.5 0.5/1 0.5/1 0.25/0.5 8(R)/16 160(R)/320 8(R)/16
221 2560(R)/5120 2560(R)/5120 2560(R)/5120 2560(R)/5120 64(R)/128 16(R)/32 32(R)/64 0.25/1
Data for Australian isolates (shaded in gray). Data for 123–182 is from a previously published study [29]. Strains 188–221
were Indian keratitis isolates. R = resistant, I = intermediate resistance. * Cipro = Ciprofloxacin, Levo = Levofloxacin,
Genta = Gentamicin, Tobra = Tobramycin, Pipera = Piperacillin, Imi = Imipenem, Ceftaz = Ceftazidime,
PMB = Polymyxin B; # = Antibiotic breakpoints for sensitive, intermediate, resistant classifications.
2.2. General Features of the Genomes
The isolates after de novo assembly consisted of different numbers of contigs ranging from 50 for
isolate 169 to 1917 for isolate 216. The average number of coding sequences was 6162 ± 359.2 for
the Australian isolates and 6544 ± 889 for the Indian isolates. Isolates had an average of 66.1% G +
C content. The tRNA copy number for the isolates ranged from 57 to 86 (which may vary between
studies that use different assembly methods). The general features of the isolates are provided in
Supplementary Table S1.
2.3. Acquired Resistance Genes
P. aeruginosa isolates were examined for horizontally acquired antibiotic resistance genes (Table 2)
using the Resfinder database. Altogether, 33 different acquired antibiotic resistance genes for various
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classes of antibiotics including aminoglycosides, fluoroquinolones, beta-lactams were found in these
isolates (Table 2).
Table 2. Acquired resistance genes in P. aeruginosa isolates from India and Australia.
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Genes 
Australian Isolates Indian Isolates 
123 126 127 162 169 176 181 182 223 224 225 227 233 235 188 189 193 198 202 206 216 217 218 219 220 221 
Aminoglycoside resistance genes 
aph(3’)-IIb                                                     
aph(6)-Id                                               l;     
rmtD2                                                     
rmtB                                                     
aph(3’)-VI                                                     
aph(3’)-lIb                                                     
aph(3’’)-Ib                                                     
aac(6’)-Ib3                                                     
aac(3)-IId                                                     
aadA1                                                     
aac(6’)-Ib-cr                                                     
Fluoroquinolone resistance genes 
crpP                                                     
qnrVC1                                                     
Beta-lactamase resistance genes 
blaPAO                                                     
blaLCR-1                                                     
blaOXA-485                                                     
blaOXA-486                                                     
blaOXA-488                                                     
blaOXA-396                                                     
blaOXA-395                                                     
blaOXA-50                                                     
blaOXA-10                                                     
blaTEM-1B                                                     
blaVIM-2                                                     
blaPME-1                                                     
blaPAU-1                                                     
Sulphonamide, tetracycline, macrolide, fosfomycin, and chloramphenicol resistance genes 
sul1                                                     
tet(G)                                                     
mph(E)                                                     
mph(A)                                                     
msr(E)*                                                     
fosA                                                     
catB                                                     
* msr(E) encodes macrolide and lincosamide resistance. Isolates shaded in grey indicate Australian strains. 
Black color represents gene presence. 
Several types of non-synonymous variations were found in the core genome of the keratitis P. 
aeruginosa isolates when compared with the reference genome of PAO1 (Table 3). These non-
synonymous mutations included single nucleotide polymorphisms (SNPs), multi-nucleotide 
polymorphisms (MNPs), deletions, insertions, and complex variations (where more than one change 
occurred at one specific location compared to the reference strain). The total variations in the isolates 
ranged from 76,080 in isolate 206 to 22,536 in isolate 181. There was a median of 26,317 (IQR = 25,681–
33,780) variations in the genomes of Australian isolates and a median of 50,006 (IQR = 26,967–50,600) 
in the Indian isolates (p = 0.09). Based on the grouping of core genome phylogeny, isolates within 
group 2 (198, 202, 219, 220, 221, 233) had the most variations. Isolate 206, which had a unique sequence 
type and was placed in a separate group by pan genome analysis, had an exceptionally high number 
of variations (76,080) and SNPs (67,271). 
Table 3. Frequency of different types of variation in the genes of P. aeruginosa isolates. 
sr(E) encodes macrolide and lincosamide resistance. Isolate shaded in grey i dicate Australian strains. Black color
represents gene presence.
An aminoglycoside resistance gene (aph(3’)-IIb), a beta-lactam resistance gene (blaPAO), a fosfomycin
resista ce gene (fosA), a d a chloramphenicol resista e (catB7) were common to all isolates.
The Australian isol es (123–182) had acquired only eight resistance genes, while the Indian isolates
(188–221) ad acquired 26 different re istance genes (Tabl 2). Five I dian isolates (198, 202, 217, 219,
and 221, with large pan genomes) acquired the largest number of resistance genes. Of these fiv i lates,
the pairs 198/219 and 202/221 had the most similar resistance gene profiles and each member of the
pair were of the same s quence type, ST308 and ST316 respectively. As acquired resistance genes may
be carrie o integrons, the genomes of the P. aeruginosa isolat s were analyzed for integrons using
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Integron Finder version 1.5.1. qnrCV1 was associated with a class 1 integron in isolates 202 and 221 and
a Tn3 transposon in isolates 198 and 219.
Several types of non-synonymous variations were found in the core genome of the keratitis
P. aeruginosa isolates when compared with the reference genome of PAO1 (Table 3). These non-synonymous
mutations included single nucleotide polymorphisms (SNPs), multi-nucleotide polymorphisms (MNPs),
deletions, insertions, and complex variations (where more than one change occurred at one specific
location compared to the reference strain). The total variations in the isolates ranged from 76,080 in
isolate 206 to 22,536 in isolate 181. There was a median of 26,317 (IQR = 25,681–33,780) variations in
the genomes of Australian isolates and a median of 50,006 (IQR = 26,967–50,600) in the Indian isolates
(p = 0.09). Based on the grouping of core genome phylogeny, isolates within group 2 (198, 202, 219, 220,
221, 233) had the most variations. Isolate 206, which had a unique sequence type and was placed in a
separate group by pan genome analysis, had an exceptionally high number of variations (76,080) and
SNPs (67,271).













123 28,279 1593 187 163 398 25,938
126 26,258 1416 164 159 355 24,164
127 25,760 1362 163 176 391 23,668
162 50,999 3481 281 257 951 46,029
169 50,283 3359 269 245 922 45,488
176 26,065 1372 168 161 342 24,022
181 22,536 1063 162 133 283 20,895
182 25,684 1359 172 180 368 23,605
223 25,672 1358 167 176 402 23,568
224 26,376 1435 163 165 353 24,260
225 28,070 1566 167 156 385 25,796
227 28,000 1560 162 154 370 25,754
233 52,392 3590 285 263 956 47,298
235 24,919 1349 162 171 354 22,883
188 25,833 1435 164 154 351 23,729
189 25,910 1458 165 155 365 23,767
193 26,567 1445 180 147 389 24,406
198 50,631 3503 280 236 945 45,667
202 49,981 3461 257 236 902 45,125
206 76,180 6449 336 371 1653 67,271
216 28,166 1548 183 164 433 25,838
217 51,119 3575 290 226 944 46,084
218 29,161 1676 182 181 430 26,692
219 50,507 3484 273 237 925 45,588
220 50,180 3452 267 234 894 45,332
221 50,030 3477 260 237 906 45,150
SNP = single nucleotide polymorphism; MNP = multi-nucleotide polymorphism. Isolate numbers highlighted in
gray are from Australia.
Non-synonymous mutations were assessed in resistance genes of the P. aeruginosa isolates
(Supplementary Table S2). There were no large differences in the mutations in resistance genes
of any of the isolates except the antibiotic efflux-related genes opmH and rosC. opmH had ≥9 mutations in
all isolates except 127, 162,169, 202, 218, 220, and 221 (mostly isolates of group 2 of core and pan genome
phylogenies except 127 and 218). rosC had 20 non-synonymous mutations including insertions/deletions
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in isolate 206, 11 in 233, and ≥5 mutations in isolates 162, 169, 176, 202, 216, 217, 219, 220, and 221
(mostly isolates of group 2 of core and pan genome phylogenies except 176, 216), but ≤3 mutations in
isolates 123, 126, 123, 181, 182, 188, 189, 193, 198, and 218 (mostly isolates of group 1 of core and pan
genome phylogenies except 198). Mutations in efflux genes encoding efflux pumps were also found,
including mexX, mexT, mexD, mexM, and mexY, although there was no significant difference between
two groups in the possession of mutations in these genes. All other mutations in the genes were random
without any association to sequence type, phylogeny, or susceptibility to antibiotics.
2.4. Possession of exoU and Mutations in the DNA Mismatch Repair System
ExoU was present in the genomes of all isolates in group 2 (core and pan genome phylogenetic
group) as well as isolates 123 and 127. All other isolates possessed exoS with the exception of isolate 126
which possessed both exoU and exoS. To address differences in the numbers of sequence variants between
the isolates, the genes involved in the DNA mismatch repair (MMR) system mutS (that encodes a protein
which binds to errors in DNA), mutL (that encodes a protein that works in synergy with MutS and
activates UvrD), and uvrD (a DNA helicase active in DNA replication) were examined. The mutations
in the MMR system included SNPs, indels, and complex variants. The number of mutations in mutL
ranged from 1 to 2 and mutations in mutS (which ranged between 0 and 2) were found in seven isolates
(Table 4). In uvrD, the number of mutations ranged between 0 and 5 (Table 4). exoU containing isolates
possessed a median of two (IQR = 1–3) mutations in mutL, zero (IQR = 0–2) mutations in mutS, and four
(IQR = 2–5) mutations in uvrD, whereas exoS containing isolates possessed a median of zero (IQR = 0–1)
mutations in mutL, zero (IQR = 0–1) mutations in mutS, and two (IQR = 0–2) median mutations in uvrD.
There were significant differences in the number of mutL (p = 0.0021) and uvrD (p = 0.02) mutations in
exoS and exoU isolates but not with mutS (p = 0.3). Isolate 206, an exoS strain and an outlier in the core
genome analysis, had one mutation in mutL. Details of mutations occurring in nucleotide and respective
proteins are provided in Supplementary Table S3.
Table 4. Possession of exoU and exoS and number and type of non-synonymous mutations in the
mismatch repair system genes in P. aeruginosa isolates.
P. aeruginosa Isolates Type III SecretionSystem Genes mutL mutS uvrD
123 exoU 1 SNP 0 1 complex
126 exoU/exoS 0 0 0
127 exoU 0 1 MNP 1 MNP, 1 complex
162 exoU 1 SNP 0 2 SNP, 1 MNP, 2 complexes
169 exoU 1 SNP 1 complex 2 SNP, 2 MNP, 1 complex
176 exoS 1 SNP 0 1 SNP
181 exoS 0 0 0
182 exoS 0 0 1 MNP 1complex
223 exoS 0 1 SNP 1 MNP, 1 complex
224 exoS 1 SNP 0 1 MNP, 1 complex
225 exoS 0 0 2 SNP, 2 MNP, 1 complex
227 exoS 0 0 2 SNP, 2 MNP, 1 complex
233 exoU 0 0 1 MNP, 1 complex
235 exoS 0 0 0
188 exoS 0 0 1 MNP, 1 complex
189 exoS 1 SNP 0 1 MNP, 1 complex
193 exoS 0 0 0
198 exoU 2 SNP 0 1 SNP, 3 complexes
202 exoU 1 SNP 1 complex 1 SNP, 2 MNP, 2 complexes
206 exoS 1 MNP 1 complex 0
216 exoS 0 0 0
217 exoU 2 SNP 1 complex 1 SNP, 2 MNP, 1 complex
218 exoS 0 0 0
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Table 4. Cont.
P. aeruginosa Isolates Type III SecretionSystem Genes mutL mutS uvrD
219 exoU 2 SNP 0 1 SNP, 1 MNP, 2 complexes
220 exoU 1 SNP 1 complex 1 SNP, 2 MNP, 2 complexes
221 exoU 1 SNP 1 complex 1 SNP, 2 MNP, 2 complexes
SNP = single nucleotide polymorphism, MNP = multinucelotide polymorphism. Isolates shaded in grey indicate
Australian strains.
2.5. Sequence Type Analysis and Phylogenetics
All Australian isolates were of different sequence types (ST), except 225 and 227 which belonged to
ST233. Among the 12 Indian isolates, one isolate was designated as belonging to a new sequence type,
two isolates (198 and 219) belonged to ST308, two others (188 and 189) belonged to ST491, and three
isolates (202, 220, and 221) belonged to ST316 (Table 5).
Table 5. Sequence types of P. aeruginosa isolates.
P. aeruginosa Isolates Sequence Types Core Genes Shell Genes Pan/Total Genes
123 ST218 5496 508 6004
126 ST2726 5483 712 6195
127 ST845 5483 938 6421
162 ST298 5439 905 6344
169 ST1027 5456 694 6150
176 ST709 5547 1112 6659
181 ST244 5588 1047 6662
182 ST27 5486 1096 6582
223 ST17 5471 1232 6703
224 ST168 5483 607 6090
225 ¤ ST233 5515 1338 6853
227 ¤ ST233 5493 1304 6797
233 NEWST 5440 624 6064
235 ST262 5470 540 6010
188 * ST491 5490 535 6025
189 * ST491 5492 531 6023
193 ST760 5490 594 6084
198 † ST308 5454 1428 6882
202 # ST316 5425 1505 6930
206 NEWST 5331 1084 6415
216 ST1527 5480 1488 6968
217 ST1047 5448 1173 6621
218 ST3083 5513 488 6001
219 † ST308 5451 1796 7247
220 # ST316 5430 948 6378
221 # ST316 5425 1511 6936
PA7 ST1196 3599 4586 8185
PA14 ST253 5436 790 6226
Gray shading denotes Australian isolates. *, †, #, ¤ indicates strains belong to the same sequence types (STs).
The number of core and total or pan (or total) genes were reported from the statistical summary
of Roary v3.11.2. The core genomes of the isolates were aligned using PA7 (Accession number
NC_009656.1), PA14 (Accession number NC_004863.1), and PAO1 (Accession number NC_002516.1) as
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reference strains. The eight published genomes of P. aeruginosa isolates from eye as well as strains from
other sources were also included. The core genes of published isolates are provided in Supplementary
Table S4. The isolates were sub-grouped based on the number of core genes; isolates with a similar
number of core genes were closely aligned and isolates with the same sequence type were grouped
together. The core genomes formed two groups in the phylogenetic tree (Figure 1). Isolates in group 1
tended to have a larger number of core genes than isolates in group 2. Isolate 206, PA57, and PA7 were
outliers based on core genome phylogeny. The Australian and Indian isolates had a similar number of
core genes, whereas the Indian isolates had a larger number of pan genes (10,889) due to the acquisition
of shell genes (genes present in two or more strains) (Table 4).
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Figure 1. Core genome phylogeny of P. aeruginosa isolates using Parsnp. PAO1 was used as reference.
PA7 and PA14 were also included.
The phylogenetic relationships of these P. aeruginosa isolates were assessed by aligning their pan
genome against PAO1 as a reference. The output generated using Roary showing the gene presence or
absence in all isolates is provided in Supplementary Figure S1. This again divided the P. aeruginosa
isolates into two major groups. Six multi-drug resistant Indian isolates (198, 202, 217, 219, 220, 221) and
the VRFPA04 isolate (isolated from the cornea) were clustered in one group, which also contained the
two Australian isolates 162 and 169. The Indian isolate 216 was categorized in a separate sub-group
due to the large number of shell genes and possession of exoS.
The second group (group 2 of the pan genome analysis) included most of the Australian (123, 126,
127, 162, 176, 181, 182, 223, 224, 225, 227, 235) and Indian (188, 189, 193, 216 218) isolates along with
reference strain PAO1 (Figure 2). Overall, the multi-drug resistant Indian isolates had a large pan
genome (total of 10,889 genes obtained from the statistical summary in Roary v3.11.2). The pan genome
grouping of isolates was broadly based on the number of pan (or total) genes and possession of either
Antibiotics 2020, 9, 600 9 of 16
exoU or exoS in each group, except two Australian isolates 123 and 127 which were in group 2 but
possessed exoU. The other exception to this grouping pattern was for isolates 181 and 182 which had
large pan genomes and were clustered into group 1 but carried exoS.
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pan genome (total of 10,889 genes obtained from the statistical summary in Roary v3.11.2). The pan 
genome grouping of isolates was broadly based on the number of pan (or total) genes and possession 
of either exoU or exoS in each group, except two Australian isolates 123 and 127 which were in group 
2 but possessed exoU. The other exception to this grouping pattern was for isolates 181 and 182 which 
had large pan genomes and were clustered into group 1 but carried exoS. 
 
Figure 2. Pan genome phylogeny of P. aeruginosa isolates. Branches with no color representation 
indicate non-ocular isolates. Red color indicates Australian, blue color represents Indian, and orange 
color represents published eye isolates. Green color represents reference strains. Purple color 
represents reference strains. 
The isolates of group 2 usually had a large number of pan genes and were exoU+. Isolates having 
similar numbers of pan genes were sub-grouped together. For example, isolate 193 (pan genes = 6084) 
and 218 (pan genes = 6001) were sub-grouped together. Isolate 218 had a similar number of pan genes 
to isolate 123 (pan genes = 6001), but isolate 218 possessed exoS, while 123 possessed exoU, and thus 
these were not grouped together. Isolates belonging to the same sequence type were also grouped 
together. The MDR isolates, the isolates with same STs, and isolates with large gene variations were 
clustered in one pan-group. The previously published isolates PA_D1, PA_D2, PA_D9, and PA_D16 
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Figure 2. Pan genome phylogeny of P. aeruginosa isolates. Branches with no color representation
indicate non-ocular isolates. Red color indicates Australian, blue color represents Indian, and orange
color represents published eye isolates. Green color represents reference strains. Purple color represents
reference strains.
The isolates of group 2 usually had a large number of pan genes and were exoU+. Isolates having
similar numbers of pan genes were sub-grouped together. For example, isolate 193 (pan genes = 6084)
and 218 (pan genes = 6001) were su -grouped together. Isolate 218 had a similar number of pan genes to
isolat 123 (pa genes = 6001), but isolate 218 possessed exoS, while 123 possessed xoU, and thus these
were not grouped together. Isolates belonging to the same sequ nce type were also grouped together.
The MDR isolates, the isolates with same STs, and isolates with large gene variations were clustered in
one pan-group. The previously published isolates PA_D1, PA_D2, PA_D9, and PA_D16 with the same
ST and those with large shell genes were grouped with the MDR isolates of the current study.
3. Discussion
This study investigated genomic differences in Australian and Indian P. aeruginosa isolates from
keratitis. Phenotypically, more resistance was found in Indian isolates compared to Australian isolates
as has been shown in previous studies [30,31]. Unregulated antibiotic use in India has been linked
to increased antibiotic resistance [32]. Resistance to antibiotics is problematic even in the treatment
of keratitis, where a topical application of antibiotics is used. Infection with antibiotic resistant
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strains results in prolonged infection [33], more severe keratitis [5], and an increase in the cost of
treatment [34,35].
Indian P. aeruginosa strains harbored more resistance genes compared to Australian isolates,
although aph(3’)-IIb, blaPAO1 (fosA), and catB7 were found in all isolates, which was consistent
with previous studies [31,36]. qnrVC1 was found in four Indian isolates but no Australian isolates.
This fluoroquinolone resistance gene has not been previously reported in P. aeruginosa ocular isolates [31],
but it has been reported in burns isolates and has been identified as being carried on an integron [37].
Similarly, in the current study qnrVC1 was carried on a class 1 integron in isolates 202 and 221,
but integrated into a Tn3 transposon in isolates 198 and 219. This gene has also been isolated from the
high risk ST773 clone of P. aeruginosa from urine in Hungary [38]. High risk clones are isolates with
high mutational rates in resistance genes and those that have acquired a large number of resistance
genes. As previously described, resistance to fluoroquinolones in keratitis P. aeruginosa isolates was also
due to mutations in the quinolone resistance determining regions of gyrA and parC [15]. Possession of
qnrVC1 and mutations in gyrA and parC were associated with high levels of fluroquinolone resistance.
The possession of large numbers of acquired resistance genes by Indian isolates likely contributed to
the higher rates of resistance of these isolates. The Indian isolates 198, 202, 217, 219, 220, and 221 also
had a high number of gene variations which is an independent mechanism of resistance.
The aminoglycoside resistance gene aph(6)-Id which encodes for streptomycin resistance was found
in six Indian isolates, including the four that carried qnrVC1, but in no Australian isolates. Previously,
aph(6)-Id was found in only one Indian ocular isolate from 1997 [31], but has been found in cystic fibrosis
P. aeruginosa isolates [39] and has been associated with the transposon Tn5393 on a plasmid in one
strain of P. aeruginosa [39]. As streptomycin is no longer used in clinical treatment [40], this resistance
may not be clinically relevant but does suggest environmental selection for the persistence of this gene.
The total number of gene variants found in the Indian isolates 198, 202, 219, and 221 were
greater than Australian isolates. However, there were a small number of SNPs found in the genes
associated with resistance for these isolates. The Indian isolate 206 (NEWST) had a high number of
SNPs in antibiotic resistance genes mexC, mexD, mexM, mexX, mexS, opmE, mexP, mexK, oprJ, ampC,
rosC, and mprF. There was no difference in the mutations of other mex genes including mexX, mexT,
mexD, mexM, and mexY between Australian and Indian isolates. Given that most isolates from both
countries, whether they were sensitive or resistant, had a similar number of mutations in the resistance
genes, it is likely that the resistance to antibiotics was related to the possession of acquired resistance
genes rather than mutations in chromosomal genes.
In the Australian isolates, four out of the eight isolates (50%) carried exoU, while one isolate was
both exoU+/exoS+ and three (38%) were exoS+. In Indian isolates, 50% carried exoU and 50% carried exoS.
A previous study has also shown an equal ratio of both genes [41] in keratitis isolates. The possession of the
exoU genotype in P. aeruginosa ocular isolates has been related to elevated resistance to disinfectants [42],
fluoroquinolones [43], and multiple antibiotics [41]. Furthermore, one study reported worst clinical
outcomes and more resistance by exoU carrying isolates [43]. The isolates of this study showed similar
findings because the exoU+ isolates 198, 202, 217, 219, 220, 221, and 233 were also MDR.
The DNA mismatch repair system (MMR) in P. aeruginosa is based on the protein trimer
MutS-MutL-UvrD and functions to correct errors and preserve the integrity of the genome [24,44,45].
The mutH component of MMR, which is important in other Gram negative bacteria, such as E. coli [46],
has not been found previously in P. aeruginosa [25] and was not present in the isolates of the current study.
Mutations in mutS, mutL and uvrD can reduce the ability of the bacterium to repair DNA lesions [46].
Strong mutator strains have defects in their MMR system and mutations in mutS predominate [47].
Mutations in the MMR can be a reason for the development of hypermutations in isolates. In cystic
fibrosis, hypermutations were found to be a key factor in the development of MDR resistant P. aeruginosa
strains [23]. Similar findings were found in this study where isolates 198, 202, 206, 219, and 221 had
mutations in the MMR genes, and these isolates had an overall larger variation in their genomes.
In the current study, isolates had more mutations in mutL and uvrD, suggesting the strains may not be
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strong mutators (which is usually associated with mutation in mutS), but nevertheless can undergo
uncorrected genetic changes. Indeed, the P. aeruginosa isolates in the current study which had mutations
in mutL and uvrD had greater numbers of SNPs, insertions and deletions, acquired genes, and had large
pan genomes. Among these isolates, 198, 202, 219, and 221 possessed either the transposon Tn3 or class
1 integrons which carried the acquired genes. This also might be due to mutated MMR, as mutations
in MMR genes increase the chances of horizontal gene transfer in mutator isolates [47]. The number of
mutations in MMR was greater in exoU possessing isolates with large gene variations. exoU is carried
on genomic islands [48,49] and these exoU carrying isolates had larger pan genomes with possession of
mobile genetic elements. Therefore, the isolates with the mutated MMR systems may have a greater
ability of strains to accumulate gene variations and the acquisition of exoU. Isolate 206, on the other
hand, possessed exoS and was not MDR but possessed a large number of SNPs and a large pan genome
with one mutation in each of mutS and mutL. Further in-depth studies are required to understand the
influence of the MMR system on genomic changes in P. aeruginosa.
Analysis of the sequence types of the P. aeruginosa ocular isolates revealed the presence of three
clones, two in the Indian and one in the Australian isolates. The isolates with the same STs had mostly
the same phenotypic and genotypic features. The exception to this was isolate 220 that had acquired
fewer resistance genes compared to the other two isolates 202 and 221 of ST316. Previously, five ocular
P. aeruginosa strains from India isolated in 1997 were of sequence type ST308 [31]. The two isolates of
ST308 in the current study, isolated in 2017 and 2018, had acquired more resistance genes compared
to isolates from 1997 [31]. This indicates that the clonal isolates have continued to evolve over this
time period, although the specific selection factors driving those changes are yet to be elucidated.
None of the isolates were collected from the same patient. The majority of the isolates with the same
STs grouped in the same phylogeny including previously published isolates (PA_D1, PA_D2, PA_D9,
P_D16) with ST1971.
Core and pan genome phylogenies of the isolates produced two almost identical groups, which
was in agreement with previously published studies [31,50]. Both phylogenies included isolates from
either Australia or India, but those in group 2 tended to be the MDR Indian isolates and possessed
higher numbers of antibiotic resistance genes. About 65% of all ocular isolates grouped together which
indicated less diversity in the ocular P. aeruginosa isolates [31,51,52]. The grouping of MDR strains
from this study with PA14 along a MDR ocular isolate VRFPA04 [36] in both core genome and pan
genome analysis, and the grouping of the sensitive strains with PAO1 along the commonly studied
cystic fibrosis isolates DK2 and LESB58, was similar to a previous study examining older isolates
from India and Australia [31]. Isolate 206, which had the smallest number of core genes and was of
a new sequence type, was an outlier in the core genome phylogeny similar to the taxonomic outlier
PA7 [53]. However, isolate 206 was grouped together with other isolates in the pan genome because
it had acquired a large number of genes. Acquired genes are part of the pan rather than the core
genome [53] and the presence of larger pan genomes in MDR P. aeruginosa isolates points towards the
acquisition of new genes [54]. Previously, a smaller core genome size of 4910 genes has been reported
in ocular P. aeruginosa isolates [31]. However, the current study found a core genome size similar to
P. aeruginosa from different sources, comprising 5316–5233 genes [55,56]. The core genome (which is
almost 90% of total genome) refers to the conserved genes present in a species [57] which might differ
in each individual strain within that species. Additionally, SNPs can be a result of poor sequencing
quality and hence it is important to have a good sequencing depth at those positions to identify them
as a mutation rather than sequencing error [58]. Grouping of all the isolates including ocular and
non-ocular remained the same in both core and pan genome phylogeny.
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4. Materials and Methods
4.1. P. aeruginosa Strains and Susceptibility Testing
Twenty-six P. aeruginosa keratitis isolates, eight isolated in Australia from 2004 to 2006, six from
2018 and 2019 (total 14 Australian isolates), and twelve isolated in India between 2017 and 2018, were
included in this study. These isolates were selected from a larger collection of strains based on their
antibiotic susceptibilities (those phenotypically resistant to multiple antibiotics, some resistant to one or
multiple antibiotics, and some which were sensitive to all antibiotics). The susceptibilities of Australian
strains (2004–2006) included in this study have been previously published [29]. Strains were selected
after comparing their susceptibilities to antibiotics that are used to treat ocular infections. For genetic
comparisons, the data of 34 P. aeruginosa isolates from eyes and other sources were also included.
The general characteristics of these isolates are described in Supplementary Table S4. The genomes
of these isolates were downloaded from the NCBI database and reannotated for this study using the
same parameters as of the isolates of this study to avoid any bias in results.
The minimum inhibitory concentration (MIC) and minimum bactericidal concentration (MBC) of
various antibiotics which are commonly used to treat P. aeruginosa keratitis [16] were assessed for the
isolates using the broth microdilution method in 96-well plates following the Clinical and Laboratory
Standard Institute guidelines [59]. The antibiotics tested were ciprofloxacin, levofloxacin, gentamicin,
ceftazidime (Sigma-Aldrich, St. Louis, MO, USA), polymyxin B (Sigma-Aldrich, Vandtårnsvej, Søborg,
Denmark), tobramycin, piperacillin (Cayman Chemical Company, Ann Arbor, MI, USA), and imipenem
(LKT Laboratories Inc., St. Paul, MN, USA). The susceptibility results were interpreted using the
EUCAST v9 [60] and CLSI [61] 2017 breakpoints.
4.2. Genomic Sequencing
DNeasy Blood and Tissue Kits (Qiagen, Hilden, Germany) were used for DNA extraction as
per the manufacturer’s recommendations. The Nextera XT DNA library preparation kit (Illumina,
San Diego, CA, USA) was used to prepare paired-end libraries. All the libraries were multiplexed on
one MiSeq run. FastQC version 0.117 (https://www.bioinformatics.babraham.ac.uk/projects/fastqc) was
used to assess the quality of sequenced genomes using raw reads. Version 0.38 of Trimmomatic [61] was
used for trimming the adapters from the reads following de novo assembly using Spades v3.13.0 [62].
Genomes were annotated using Prokka v1.12 [63].
Sequence types were investigated using PubMLST https://pubmlst.org/. Pan genomes of the
P. aeruginosa isolates were analyzed using Roary v3.11.2 [64] using PAO1 as a reference, while core
genome phylogeny was constructed using Harvest Suite Parsnp v1.2 [65] with strains PAO1, PA7,
and PA14 used as reference strains. The output file ‘genes_ presence_absence’ was used to compare the
P. aeruginosa isolates. Acquired resistance genes were identified using the online database Resfinder v3.1
(Centre for Genomic Epidemiology, DTU, Denmark) [66]. Integron Finder v1.5.1 was used to identify
any integrons present in the isolates. Mutations in the genes were detected using Snippy V2 [67].
Isolates with same sequence types were compared for nucleotide similarities using the MUMmer
online web tool (http://jspecies.ribohost.com/jspeciesws/#analyse).
Using the Pseudomonas genome database (http://www.pseudomonas.com) and comprehensive
antibiotic resistance database (https://card.mcmaster.ca), 76 genes related to P. aeruginosa resistance were
selected to investigate the presence of single nucleotide polymorphisms. All isolates were analyzed
for the presence of the type III secretion system associated virulence factors exoU and exoS using the
BlastN database.
4.3. Statistical Analysis
The statistical analysis was performed using GraphPad Prism v8. Medians were calculated with
the ‘descriptive statistics’ option during analysis of variance (ANOVA). P-values less than 0.05 were
considered as significant. Fischer’s Exact test was used to find the difference between acquired genes.
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To analyze the significant difference in the DNA mismatch repair genes between exoU and exoS isolates
and gene variations in the isolates, the Mann–Whitney test was used.
5. Conclusions
Indian isolates and Australian isolates were clearly distinct in carrying a type III secretion system
related to exoU and exoS. There was an association in the isolates for carrying acquired resistance genes
with a large number of pan genes. Indian isolates were more resistant to antibiotics compared to
Australian isolates. Additionally, isolates of P. aeruginosa from ocular infection had a large number of
genetic variations (mutations) and a mutated mismatch repair system. However, the isolates collected
from the same region or time will give a clearer idea of these differences.
Supplementary Materials: The following are available online at http://www.mdpi.com/2079-6382/9/9/600/s1,
Table S1: Details of the Pseudomonas aeruginosa isolates used in the current study. Table S2: Gene variations
of resistance genes in Pseudomonas aeruginosa isolates (the gray-shaded strains were isolated from Australia).
Nucleotide accession: The nucleotide sequences are available in the GenBank under the Bio project accession
number PRJNA590804. Table S3: Types of mutations in the mismatch repair system; Table S4: Genomics features
of P. aeruginosa isolates; Figure S1: Pan-genome phylogenetic tree. The data on the right of the figure shows the
presence and absence of genes. The tree was built using the genome of PAO1 as a reference.
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